((自动化翻译由路透提供,请见免责声明 ))
1月16日 - ** 制药商Atara Biotherapeutics 股价盘前下跌47.8%至6.87美元
** 美国 FDA 拒绝批准 (link) 公司的癌症疗法 tabelecleucel
** 美国食品和药物管理局的决定是基于对该疗法的第三方生产设施进行检查时观察到的结果。
** 如果到2025年第一季度ATRA仍无法获得足够的资金,公司打算暂停所有CAR-T细胞治疗项目,并大幅削减开支和活动,只开展那些支持tabelecleucel获得批准的项目。
** 2024 年股价上涨 3.8
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.